Highlights of the Comparative Analysis
The management of central precocious puberty (CPP) has seen a significant shift toward long-acting formulations to improve patient quality of life. The recent UK multicentre retrospective cohort study provides several critical insights for clinicians:
1. Clinical Equivalence: The 24-weekly administration of Decapeptyl SR (22.5 mg) provides suppression of the hypothalamic-pituitary-gonadal (HPG) axis equivalent to the traditional 12-weekly (11.25 mg) regimen.
2. Stable Anthropometrics: No significant differences were observed in height velocity, body mass index (BMI) SDS, or Tanner staging progression between the two groups.
3. Patient Preference: 100% of patients and families who expressed a preference favored the 24-weekly schedule, citing reduced injection frequency and less disruption to daily life.
4. Safety and Tolerability: Both regimens were well-tolerated, with no new safety signals identified for the longer-acting preparation.
